Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Repository of the University of Ljubljana
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Advanced
New in RUL
About RUL
In numbers
Help
Sign in
Details
Non-thermal ablation and drug delivery by electroporation : expanding current indications beyond cancer and cardiac treatment
ID
Miklavčič, Damijan
(
Author
),
ID
Cindrič, Helena
(
Author
),
ID
Davalos, Rafael V.
(
Author
),
ID
Deschamps, Frederic
(
Author
),
ID
Gehl, Julie
(
Author
),
ID
Kos, Bor
(
Author
),
ID
Kramar, Peter
(
Author
),
ID
Kuhelj, Dimitrij
(
Author
),
ID
Meijerink, Martijn R.
(
Author
),
ID
Soden, Declan M.
(
Author
),
ID
Štabuc, Miha
(
Author
),
ID
Serša, Gregor
(
Author
)
PDF - Presentation file,
Download
(1,42 MB)
MD5: 313C88C42234DB4B4C568696011E2207
URL - Source URL, Visit
https://reference-global.com/article/10.2478/raon-2026-0040
Image galllery
Abstract
Background. Electroporation-Based Treatments and Therapies (EBTTs) – electrochemotherapy, irreversible electroporation, pulsed field ablation, and gene electro-transfer – use short, high-voltage electric pulses to permeabilize cell membranes, enabling non-thermal tissue ablation and enhanced local drug delivery. Although EBTTs have been used clinically for over three decades, primarily in oncology, their adoption remains limited compared to thermal ablation modalities. In contrast, cardiac pulsed field ablation (PFA) has seen rapid adoption since the first FDA device approval in December 2023. Conclusions. This expert opinion paper reviews the current clinical landscape of EBTTs in oncology and cardiac arrhythmia treatments, and focuses on emerging non-oncological and non-cardiac applications, including endoscopic pulsed electric field therapy for type 2 diabetes, bronchial rheoplasty for chronic bronchitis, bleomycin electrosclerotherapy for vascular malformations, nanosecond PFA for benign thyroid nodules, and electroporation-mediated gene delivery – and identifies key barriers to wider adoption: insufficient randomized evidence, lack of validated treatment planning tools, fragmented reimbursement, and limited standardization. We outline measures to facilitate clinical translation.
Language:
English
Keywords:
elektroporacija
,
ablacija s pulzirajočim poljem
,
elektrokemoterapija
,
ireverzibilna elektroporacije
,
genska elektrotransfekcija
Work type:
Article
Typology:
1.02 - Review Article
Organization:
FE - Faculty of Electrical Engineering
Publication status:
Published
Publication version:
Version of Record
Publisher:
Association of Radiology and Oncology
Year:
2026
Number of pages:
str. 319-322
Numbering:
Vol. 60, no. 3
PID:
20.500.12556/RUL-186665
UDC:
602.621
ISSN on article:
1318-2099
DOI:
10.2478/raon-2026-0040
COBISS.SI-ID:
287787523
Publication date in RUL:
04.09.2026
Views:
61
Downloads:
7
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Radiology and oncology
Shortened title:
Radiol. oncol.
Publisher:
Association of Radiology and Oncology
ISSN:
1318-2099
COBISS.SI-ID:
32649472
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
electroporation
,
pulsed field ablation
,
electrochemotherapy
,
irreversible electroporation
,
gene electrotransfer
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back